NASDAQ:ENLV

Enlivex Therapeutics Stock Insider Trading

etoro logo Buy ENLV
*Your capital is at risk
$0.85
+0.0001 (+0.0118%)
At Close: Jun 03, 2026

Enlivex Therapeutics Stock Insider Power

Based on the 33 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 1.62M and sold 112.78K ENLV shares in the last 33 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 33 transactions)
100.00
Buy 1.62M shares
Sell 112.78K shares
94% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Hart Gili
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Galamidi Einat
Chief Medical Officer
Officer 0
Value: $0
Mar 18, 2026
Buy
Option (right to buy)
Havron Avraham
Director
Director 3 382
Value: $18.1K
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Havron Avraham
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Hershkovitz Oren
Chief Executive Officer
CEO / President 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 0
Value: $0
Mar 18, 2026
Buy
Option (right to buy)
Hart Gili
Director
Director 3 382
Value: $18.1K
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Novik Shai A
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, par value NIS 0.40 per share
Pomerantz Roger
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Option (right to buy)
Pomerantz Roger
Director
Director 150 000
Value: $895.1K
Nov 24, 2025
Buy
Employee Stock Option (right to buy)
Galamidi Einat
Chief Medical Officer
Officer 25 000
Value: $133.5K
Nov 24, 2025
Buy
Employee Stock Option (right to buy)
Hershkovitz Oren
Chief Executive Officer
CEO / President 60 000
Value: $320.4K
Nov 24, 2025
Buy
Employee Stock Option (right to buy)
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 10 000
Value: $32.1K
Nov 24, 2025
Buy
Employee Stock Option (right to buy)
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 7 500
Value: $40.1K
Nov 24, 2025
Buy
Employee Stock Option (right to buy)
Galamidi Einat
Chief Medical Officer
Officer 10 000
Value: $32.1K
Nov 17, 2025
Buy
Option (right to buy)
Novik Shai A
Director
Director 250 000
Value: $1.34M
May 28, 2024
Buy
Option (right to buy)
Novik Shai A
Director
Director 250 000
Value: $3.06M
Mar 30, 2024
Buy
Employee Stock Option (right to buy)
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 5 000
Value: $23.4K
Nov 16, 2023
Buy
Employee Stock Option (right to buy)
Hershkovitz Oren
Chief Executive Officer
CEO / President 150 000
Value: $1.23M
May 03, 2023
Buy
Option (right to buy)
Novik Shai A
Director
Director 250 000
Value: $915.0K
Dec 10, 2022
Buy
Employee Stock Option (right to buy)
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 1 452
Value: $14.7K
Dec 12, 2021
Buy
Employee Stock Option (right to buy)
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 1 452
Value: $9K
Dec 12, 2021
Buy
Option (right to buy)
Novik Shai A
Director
Director 145 237
Value: $903.4K
Mar 07, 2021
Buy
Employee Stock Option (right to buy)
Shlosberger Shachar
Chief Financial Officer
C-Suite Officer 1 452
Value: $4K
Jun 01, 2019
Buy
Option (right to buy)
Havron Avraham
Director
Director 53 192
Value: $143.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ENLIVEX THERAPEUTICS LTD.
Enlivex Therapeutics
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel....
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE